tert-butyl 3-methyl-5-(trimethylstannyl)-1H-indazole-1-carboxylate | 855292-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: tert-butyl 3-methyl-5-(trimethylstannyl)-1H-indazole-1-carboxylate
• 英文别名: 3-Methyl-5-trimethylstannanyl-indazole-1-carboxylic Acid Tert-Butyl Ester；3-methyl-5-trimethylstannyl-indazole-1-carboxylic acid tert-butyl ester；Tert-butyl 3-methyl-5-trimethylstannylindazole-1-carboxylate
• CAS: 855292-59-0
• 化学式: C₁₆H₂₄N₂O₂Sn
• 分子量: 395.089
• InChiKey: FCZBYBMPKCBLFR-UHFFFAOYSA-N

物化性质

• 沸点：
  417.4±55.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.67
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-methyl-5-(trimethylstannyl)-1H-indazole-1-carboxylate 在 tris(dibenzylideneacetone)dipalladium (0) 、 copper(I) bromide dimethylsulfide complex 、 三(邻甲基苯基)磷 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.67h， 生成 (1S)-1-(2,3-difluorobenzyl)-2-(5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)ethylamine tristrifluoroacetate
  参考文献：
  名称：

  Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension

  摘要：

  Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising efficacy was observed in vivo, this compound showed effects on depolarization of Purkinje fibers in an in vitro assay and CV hypotension in vivo. Guided by an X-ray structure of 7 bound to protein kinase A, which has 80% homology with Akt in the kinase domain, our efforts have focused on structure-activity relationship (SAR) studies of the phenyl moiety, in an attempt to address the cardiovascular liability and further improve the Akt potency. A novel and efficient synthetic route toward diversely substituted phenyl derivatives of 7 was developed utilizing a copper-mediated aziridine ring-opening reaction as the key step. To improve the selectivity of these Akt inhibitors over other protein kinases, a nitrogen atom was incorporated into selected phenyl analogues of 7 at the C-6 position of the methyl indazole scaffold. These modifications resulted in the discovery of inhibitor 37c with greater potency (IC50 = 0.6 nM vs Akt), selectivity, and improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors will be discussed.

  DOI：

  10.1021/jm0701019
• 作为产物：
  描述：

  5-溴-1H-吲唑-1-羧酸叔丁酯 在 Pd(PPh3)4 六甲基二锡 作用下， 以 甲苯 为溶剂， 以77%的产率得到tert-butyl 3-methyl-5-(trimethylstannyl)-1H-indazole-1-carboxylate
  参考文献：
  名称：

  Kinase inhibitors

  摘要：

  具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。

  公开号：

  US20030187026A1

文献信息

• Substituted diazabicycloalkane derivatives
  申请人：Basha Anwer

  公开号：US20050101602A1

  公开（公告）日：2005-05-12

  Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

  式(I)的化合物 Z-Ar 1 —Ar 2 (I) 其中Z是一种二氮杂双环胺，Ar 1 是一个5-或6-成员芳香环，Ar 2 选自未取代或取代的5-或6-成员杂芳基环；未取代或取代的双环杂芳基环；3,4-(亚甲二氧基)苯基；咔唑基；四氢咔唑基；萘基；和苯基；其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的病症或紊乱中有用。还公开了包含式(I)的化合物的药物组合物以及使用这些化合物和组合物的方法。
• Fused bicycloheterocycle substituted quinuclidine derivatives
  申请人：Ji Jianguo

  公开号：US20050137204A1

  公开（公告）日：2005-06-23

  Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N + —O − ; X is O, S, —NH—, and —N-alkyl-; Ar 1 is a 6-membered aromatic ring; and Ar 2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

  式(I)的化合物，其中n为0、1或2；A为N或N+—O−；X为O、S、—NH—和—N-烷基-；Ar1为6-成员芳香环；Ar2为融合的双环杂环。这些化合物在治疗α7 nAChR配体预防或改善的病症或疾病中很有用。还公开了具有式(I)化合物的药物组合物以及使用这些化合物和组合物的方法。
• WO2006/65233
  申请人：——

  公开号：——

  公开（公告）日：——